3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
4
Terminated
2
Recruiting
2
Not yet recruiting
2
Completed
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
3
Gastrointestinal
3
Thoracic
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Interventions
Paclitaxel
20
Carboplatin
20
Bevacizumab
13
Radiotherapy
12
Cisplatin
11
Cyclophosphamide
8
olaparib
6
niraparib
6
Taxes
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Biopsy
5
talazoparib
4
dostarlimab
4
aldesleukin
4
Specimen Handling
4
Fulvestrant
4
Doxorubicin
4
fludarabine
3
atezolizumab
3
Topotecan
3
Radiation
3
NVP-BKM120
3
Methods
3
Metformin
3
Letrozole
3
Hyperthermic Intraperitoneal Chemotherapy
3
Early Intervention, Educational
3
Colposcopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
tislelizumab
×
Gynecologic
×
Clear all
NCT05614453
2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2
Withdrawn